Teva Pharmaceutical Industries Limited (BUL:TEVA)
Bulgaria · Delayed Price · Currency is EUR | Market Cap | 47.05B +157.4% |
| Revenue (ttm) | 15.17B +2.7% |
| Net Income | 445.58M -29.0% |
| EPS | 0.39 -30.8% |
| Shares Out | n/a |
| PE Ratio | 91.15 |
| Forward PE | 15.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 35.30 |
| Previous Close | 35.00 |
| Day's Range | 35.30 - 35.30 |
| 52-Week Range | 34.60 - 35.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About BUL:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva price target raised to $56 from $44 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $56 from $44 and keeps an Overweight rating on the shares. The firm attended Teva’s R&D Day, where the…
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
Alvotech initiated with a Buy at Jefferies
Jefferies initiated coverage of Alvotech (ALVO) with a Buy rating and $9 price target. U.S. biosimilars Humira and Stelara are growing steadily due to partner Teva‘s (TEVA) solid execution, says…
Teva price target raised to $57 from $55 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Teva (TEVA) to $57 from $55 and keeps a Buy rating on the shares. The firm said Teva announced…
Teva price target raised to $48 from $43 at BofA
BofA raised the firm’s price target on Teva (TEVA) to $48 from $43 and keeps a Buy rating on the shares.
Teva price target raised to $55 from $50 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Teva (TEVA) to $55 from $50 and keeps a Buy rating on the shares. Austedo sales are expected to face near-term volatility…
Teva price target raised to $54 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Teva (TEVA) to $54 from $52 and keeps a Buy rating on the shares. The firm says the Q3 report “reflected the…
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyski...
Teva says ‘very confident’ in trajectory of biosimilars business
09:11 EST Teva (TEVA) says ‘very confident’ in trajectory of biosimilars business
Teva reports Q3 EPS 86c, consensus 72c
Reports Q3 revenue $4.4B, consensus $4.23B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action an...
Teva sees FY26 EPS $1.92-$2.11, consensus $2.09
Sees FY26 revenue $16.7B-$17B, consensus $16.66B. Sees FY26 adjusted EBITDA $4.23B-$4.43B. Francis added: “At the same time, we are continuously building the next phase of sustainable growth at Teva (...
Teva Pharmaceutical Q3 profit gain beats estimates
Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in c...
Teva, Samsung Bioepis enter pact to commercialize infliximab-abda and Eticovo
Teva (TEVA) and Samsung Bioepis announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade a...
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's...
Teva setback does not alter Buy thesis, says H.C. Wainwright
H.C. Wainwright says discontinuation of the Phase 2 multiple system atrophy study following an interim futility analysis is a setback for Teva (TEVA) but has a limited impact on the…
Teva to discontinue mid-stage neurodegenerative disorder study
Teva said on Monday it was discontinuing its mid-stage neurodegenerative disorder study due to a low probability of the study meeting its main goal if continued.
Teva to discontinue TOPAS-MSA study
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating emrusolmin in adults with multiple system atrophy, or MSA. The decision...
Teva initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Teva (TEVA) with a Buy rating and $52 price target The firm believes Teva can continue to drive revenue growth from Austedo above Street expectations.
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
Teva to Host R&D Day on Wednesday, November 11 in New York City
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D D...
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva said on Friday it had received approval from the US Food and Drug Administration for its Weltruza drug for extended-release injectable suspension as the first and only once-monthly subcuta...
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophr...
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neuro...
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-...
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered i...